Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Islet Cell Transplant for Type 1 Diabetes
NCT01206101Phase 2Terminated
- Sponsor
- Novo Nordisk
- Start
- Mar 2012
- Primary completion
- Jun 2013
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant at 52 weeks. Started Mar 2012; status: terminated.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01206101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206101.